0001209191-21-015471.txt : 20210301
0001209191-21-015471.hdr.sgml : 20210301
20210301200033
ACCESSION NUMBER: 0001209191-21-015471
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210226
FILED AS OF DATE: 20210301
DATE AS OF CHANGE: 20210301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Taylor Stacy L
CENTRAL INDEX KEY: 0001799081
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 21700613
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVENUE E SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-26
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001799081
Taylor Stacy L
C/O ADAPTIVE BIOTECHNOLOGIES
1551 EASTLAKE AVE E STE 200
SEATTLE
WA
98102
0
1
0
0
SVP and General Counsel
Common Stock
2021-02-26
4
M
0
1041
7.80
A
2341
D
Common Stock
2021-02-26
4
M
0
1771
6.55
A
4112
D
Common Stock
2021-02-26
4
S
0
1079
54.47
D
3033
D
Common Stock
2021-02-26
4
S
0
400
55.46
D
2633
D
Common Stock
2021-02-26
4
S
0
1333
56.40
D
1300
D
Stock Option (Right to Buy)
7.80
2021-02-26
4
M
0
1041
0.00
D
2029-04-23
Common Stock
1041
27084
D
Stock Option (Right to Buy)
6.55
2021-02-26
4
M
0
1771
0.00
D
2028-04-24
Common Stock
1771
23021
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.00 to 54.855, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.025 to 55.66, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.01 to 56.66, inclusive.
The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Stacy L. Taylor by Eric Billings as attorney-in-fact
2021-03-01